IDRA : Summary for Idera Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Idera Pharmaceuticals, Inc. (IDRA)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.69+0.01 (+0.60%)
At close: 4:00 PM EST
People also watch:
CPRXHALOFOLDSYNGALE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.68
Open1.68
Bid1.70 x 500
Ask1.75 x 3000
Day's Range1.67 - 1.75
52 Week Range1.19 - 4.00
Volume576,865
Avg. Volume1,674,876
Market Cap249.53M
Beta2.66
PE Ratio (TTM)-3.99
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube10 hours ago

    ETFs with exposure to Idera Pharmaceuticals, Inc. : December 9, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Idera Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IDRA-US. Comparing the performance and risk of Idera Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q3, 2016 By the Numbers : December 8, 2016
    Capital Cube2 days ago

    Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q3, 2016 By the Numbers : December 8, 2016

    Categories: Yahoo Finance Get free summary analysis Idera Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Idera Pharmaceuticals, Inc. – Dynavax Technologies Corporation, Ionis Pharmaceuticals, Inc., Amgen Inc., Agenus Inc., Abbott Laboratories, Windtree Therapeutics, Inc., Merck & Co., Inc., Biogen Inc., Pfizer Inc. and ... Read more (Read more...)

  • Why Idera Pharmaceuticals (IDRA) Could Be Positioned for a Surge
    Zacks7 days ago

    Why Idera Pharmaceuticals (IDRA) Could Be Positioned for a Surge

    Idera Pharmaceuticals (IDRA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.